# Combined RoB Escalation Packet — GLP-1 Neuropsychiatric Safety Review
**Human adjudication queue across all newly scored studies (Stream A RCT + Stream A obs + Stream D rescore).**
14 escalated domain-cells across 9 studies. Each entry below shows both reviewers' signalling answers with verbatim quotes, the failed reconciliation, and the blinded judge's escalation reason. Fill in the 'Your call' line.

---


# ==================== A-RCT (RoB2) ====================

# Escalation packet - human review queue

5 domain-cell(s) where the two reviewers disagreed, the reconciliation round failed to converge, and the blinded judge declined to resolve on the verified evidence. For each, the judge names the deciding signalling question and what evidence is missing; choose among the candidate ratings and fill in 'Your call'.

## 27005405 - D2 (Bias due to deviations from intended interventions (effect of assignment to intervention))

- **Reviewer 1 (claude:claude-opus-4-8)**: Low  ->(after reconciliation) Some concerns
- **Reviewer 2 (openai:gpt-5.6-sol)**: High
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> All signalling-question quotes are flagged as unverified/not found except Reviewer B's 2.7 quote, which is a bare data fragment that doesn't clearly support a 'Y' rating on its own; with no verified evidence establishing responses to 2.1-2.6, the domain rating is underdetermined and requires human review of the source text.

**Reviewer 1 rationale.** The trial was double-blind for participants, site personnel and sponsor, and analyses included all randomized participants.

Reviewer 1 signalling answers:
    - **2.1** `[N]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **2.2** `[N]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **2.3** `[NA]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **2.4** `[NA]`: "NO EVIDENCE IN TEXT"
    - **2.5** `[NA]`: "NO EVIDENCE IN TEXT"
    - **2.6** `[Y]` [NOT VERIFIED IN TEXT]: "The efficacy analyses were performed on the data from the full analysis set, which included all randomized participants."
    - **2.7** `[NA]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** The safety analysis was not an assignment-based analysis because it excluded randomized participants who were not exposed. Given the single neuropsychiatric event, even a small number of exclusions could materially change the result.

Reviewer 2 signalling answers:
    - **2.1** `[N]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **2.2** `[N]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **2.3** `[NA]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **2.4** `[NA]`: "NO EVIDENCE IN TEXT"
    - **2.5** `[NA]`: "NO EVIDENCE IN TEXT"
    - **2.6** `[N]` [NOT VERIFIED IN TEXT]: "The safety analysis set included all randomized participants who were exposed to ⩾1 dose(s) of trial drug."
    - **2.7** `[Y]` [verbatim]: "Depression suicidal 1 (0.6) 1 1.1 0 0 0"

**Candidate ratings:** High | Low | Some concerns
**Your call:** ____________   **Note:** ____________

---

## 27005405 - D4 (Bias in measurement of the outcome)

- **Reviewer 1 (claude:claude-opus-4-8)**: Some concerns
- **Reviewer 2 (openai:gpt-5.6-sol)**: Low
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> judge output unparseable (JSONDecodeError('Expecting property name enclosed in double quotes: line 1 column 285 (char 284)'))

**Reviewer 1 rationale.** Assessors were blinded and ascertainment was symmetric between groups, but the reported neuropsychiatric events rely on spontaneous adverse-event reporting rather than the systematically applied validated instruments, a recognized source of under-ascertainment bias for psychiatric outcomes.

Reviewer 1 signalling answers:
    - **4.1** `[PY]` [NOT VERIFIED IN TEXT]: "Safety assessments included adverse events (AEs), standard laboratory tests, physical examinations, electrocardiograms and mental health (Patient Health Questionnaire-9 and Columbia Suicide Severity Rating Scale)."
    - **4.2** `[PN]` [NOT VERIFIED IN TEXT]: "Adverse events are treatment-emergent, defined as an event that has onset date on or after the first day of randomized treatment and no later than 14 days after the last day of randomized treatment."
    - **4.3** `[N]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **4.4** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.5** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.1** `[PY]` [NOT VERIFIED IN TEXT]: "No notable differences between liraglutide and placebo were observed during mental health evaluations with Patient Health Questionnaire-9 and Columbia Suicide Severity Rating Scale."

**Reviewer 2 rationale.** Named mental-health instruments, including the Columbia Suicide Severity Rating Scale, were used, and assessors were blinded. There is no indication that ascertainment differed between groups.

Reviewer 2 signalling answers:
    - **4.1** `[N]` [NOT VERIFIED IN TEXT]: "Safety assessments included adverse events (AEs), standard laboratory tests, physical examinations, electrocardiograms and mental health (Patient Health Questionnaire-9 and Columbia Suicide Severity Rating Scale)."
    - **4.2** `[PN]` [NOT VERIFIED IN TEXT]: "Safety assessments included adverse events (AEs), standard laboratory tests, physical examinations, electrocardiograms and mental health (Patient Health Questionnaire-9 and Columbia Suicide Severity Rating Scale)."
    - **4.3** `[N]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **4.4** `[NA]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."
    - **4.5** `[NA]` [NOT VERIFIED IN TEXT]: "In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments."

**Candidate ratings:** Low | Some concerns
**Your call:** ____________   **Note:** ____________

---

## 28910237 - D3 (Bias due to missing outcome data)

- **Reviewer 1 (claude:claude-opus-4-8)**: Some concerns  ->(after reconciliation) High
- **Reviewer 2 (openai:gpt-5.6-sol)**: High  ->(after reconciliation) Some concerns
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Both reviewers rely on the same or unrelated verified quotes to answer multiple distinct signalling questions (3.1/3.2/3.4 reuse one AE-reporting quote; 3.3 quotes differ in substance), so it is unclear whether the quotes actually establish differential missingness tied to the true outcome value. The verified evidence does not unambiguously discriminate between 'Some concerns' and 'High', so this should be escalated.

**Reviewer 1 rationale.** The text is entirely silent on any neuropsychiatric outcome, so completeness of data for that outcome cannot be established, and silence is not reassurance; general follow-up completeness (96.2% completed, 98.8% vital status) applies to cardiovascular endpoints, not to the psychiatric outcome being assessed.

Reviewer 1 signalling answers:
    - **3.1** `[NI]` [verbatim]: "Information on other nonserious adverse events was not collected (details are provided in Section 10.3 in the protocol)."
    - **3.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **3.3** `[PY]` [verbatim]: "Patients were followed for adverse events until the end of the trial or 70 days after discontinuation of the trial regimen."
    - **3.4** `[NI]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** Nonserious adverse events were not collected, creating extensive missing data for outcomes such as ideation, depression, and anxiety. Missingness likely depended on event severity and therefore on the true outcome value.

Reviewer 2 signalling answers:
    - **3.1** `[N]` [verbatim]: "Information on other nonserious adverse events was not collected (details are provided in Section 10.3 in the protocol)."
    - **3.2** `[N]` [verbatim]: "Information on other nonserious adverse events was not collected (details are provided in Section 10.3 in the protocol)."
    - **3.3** `[Y]` [verbatim]: "This category included all patients who had at least one serious adverse event that was reported during the overall period, which was defined as the period from the date of randomization through the last date that the patient was known to be alive."
    - **3.4** `[PY]` [verbatim]: "Information on other nonserious adverse events was not collected (details are provided in Section 10.3 in the protocol)."

**Candidate ratings:** High | Some concerns
**Your call:** ____________   **Note:** ____________

---

## 26630143 - D4 (Bias in measurement of the outcome)

- **Reviewer 1 (claude:claude-opus-4-8)**: Some concerns
- **Reviewer 2 (openai:gpt-5.6-sol)**: High
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Both reviewers' key signal for 4.2 (assessor blinding to intervention) is an unverified quote, so neither 'Some concerns' nor 'High' is supported by verified evidence alone; 4.3 verified quote only confirms double-blind design but its bearing on outcome-assessor knowledge is contested between reviewers (N vs NA), leaving the domain rating underdetermined.

**Reviewer 1 rationale.** Although the trial was double-blind, the neuropsychiatric outcome relied on spontaneous MedDRA-coded adverse-event reporting rather than a systematic validated instrument, which is a recognized source of bias (undercounting) for rare psychiatric events; the psychiatric-event category was not among the independently adjudicated endpoints.

Reviewer 1 signalling answers:
    - **4.1** `[PY]` [verbatim]: "Events were assessed with the use of the classifications in the Medical Dictionary  for Regulatory Activities (MedDRA), version 15.0."
    - **4.2** `[PN]` [NOT VERIFIED IN TEXT]: "Separate independent committees  whose members were unaware of the study‑group assignments adjudicated potential cardio­vascular, pancreatic, and allergic events"
    - **4.3** `[N]` [verbatim]: "The Evaluation of Lixisenatide in Acute Coronary  Syndrome (ELIXA) trial was a multicenter, ran­domized, double-blind, placebo-controlled trial"
    - **4.4** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.5** `[NA]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** The reported result was only a broad MedDRA serious psychiatric-event category, with 5 versus 9 events, and no systematic validated assessment of suicidality, depression, or anxiety was described. Such ascertainment could materially underdetect rare psychiatric outcomes despite being applied similarly across blinded groups.

Reviewer 2 signalling answers:
    - **4.1** `[Y]` [verbatim]: "Events were assessed with the use of the classifications in the Medical Dictionary for Regulatory Activities (MedDRA), version 15.0."
    - **4.2** `[PN]` [NOT VERIFIED IN TEXT]: "Patients were randomly assigned, in a double-blind manner, to once-daily subcutaneous injections of lixisenatide or volume-matched placebo."
    - **4.3** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.4** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.5** `[NA]`: "NO EVIDENCE IN TEXT"

**Candidate ratings:** High | Some concerns
**Your call:** ____________   **Note:** ____________

---

## 33567185 - D3 (Bias due to missing outcome data)

- **Reviewer 1 (claude:claude-opus-4-8)**: Some concerns  ->(after reconciliation) Low
- **Reviewer 2 (openai:gpt-5.6-sol)**: Low  ->(after reconciliation) Some concerns
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Reviewer A's verified quote (94.3% completion) only supports a 'Low' answer to 3.1 but does not verify 3.2-3.4, which require information on whether missing data caused bias, not just the completion rate; Reviewer B's answers are entirely unverified ('NO EVIDENCE IN TEXT'). Neither reviewer provides sufficient verified evidence to determine the full domain rating, so this should be escalated.

**Reviewer 1 rationale.** The text is silent on completeness of any neuropsychiatric outcome; silence is not reassurance, and spontaneous capture of rare psychiatric events is prone to differential under-ascertainment.

Reviewer 1 signalling answers:
    - **3.1** `[NI]`: "NO EVIDENCE IN TEXT"
    - **3.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **3.3** `[Y]`: "NO EVIDENCE IN TEXT"
    - **3.4** `[NI]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** Trial completion was 94.3%, supporting availability of data for nearly all participants. Limitations from restricting adverse events to on-treatment periods are addressed under deviations from intended interventions rather than participant-level missingness.

Reviewer 2 signalling answers:
    - **3.1** `[PY]` [verbatim]: "Overall, 94.3% of the participants completed the trial"
    - **3.2** `[NA]` [verbatim]: "Overall, 94.3% of the participants completed the trial"
    - **3.3** `[NA]` [verbatim]: "Overall, 94.3% of the participants completed the trial"
    - **3.4** `[NA]` [verbatim]: "Overall, 94.3% of the participants completed the trial"

**Candidate ratings:** Low | Some concerns
**Your call:** ____________   **Note:** ____________

---



# ==================== A-obs (ROBINS-I) ====================

# Escalation packet - human review queue

6 domain-cell(s) where the two reviewers disagreed, the reconciliation round failed to converge, and the blinded judge declined to resolve on the verified evidence. For each, the judge names the deciding signalling question and what evidence is missing; choose among the candidate ratings and fill in 'Your call'.

## 30728788 - D1 (Bias due to confounding)

- **Reviewer 1 (claude:claude-opus-4-8)**: Critical
- **Reviewer 2 (openai:gpt-5.6-sol)**: Serious
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Every quote from both reviewers is flagged [QUOTE NOT FOUND IN TEXT], so none of the signalling-question answers (1.1-1.8) are verified against the source text. With no verified evidence to support either the 'Serious' or 'Critical' rating, the rating is underdetermined and must be escalated.

**Reviewer 1 rationale.** There is no comparator group and no adjustment for any confounding domain (including baseline psychiatric history or co-medication), so the effect of liraglutide on neuropsychiatric outcomes cannot be distinguished from confounding. For a single-arm study with only unadjusted within-group tests, confounding is at critical risk.

Reviewer 1 signalling answers:
    - **1.1** `[Y]` [NOT VERIFIED IN TEXT]: "This was a retrospective study involving individuals with bipolar or major depressive disorder who received liraglutide."
    - **1.2** `[N]` [NOT VERIFIED IN TEXT]: "Patients weight and BMI were registered at four different time-points: baseline, i.e., when liraglutide was started (T0), and then after 1 (T1), 3 (T2), and 6 months (T3)."
    - **1.3** `[PY]` [NOT VERIFIED IN TEXT]: "The reasons for discontinuation among 15 study participants who did not complete 90 day of treatment were primarily due to treatment ineffectiveness and/or undesirable side effects related with liraglutide use."
    - **1.4** `[N]` [NOT VERIFIED IN TEXT]: "Descriptive statistics, Wilcoxon signed-rank test and Fisher exact test were performed."
    - **1.5** `[NA]`: "NO EVIDENCE IN TEXT"
    - **1.6** `[N]` [NOT VERIFIED IN TEXT]: "Descriptive statistics, Wilcoxon signed-rank test and Fisher exact test were performed."
    - **1.7** `[N]` [NOT VERIFIED IN TEXT]: "Descriptive statistics, Wilcoxon signed-rank test and Fisher exact test were performed."
    - **1.8** `[NA]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** The single-arm, retrospective analysis did not control any important confounders for the neuropsychiatric result. This creates serious concern about confounding by indication and psychiatric severity or comedication.

Reviewer 2 signalling answers:
    - **1.1** `[Y]` [NOT VERIFIED IN TEXT]: "However, our research has several limitations that should be acknowledged, including: (1) the small sample size, which clearly does not permit to consider our sample as representative of all patients with mood disorders; (2) the retrospective and non-randomized design; (3) the absence of a placebo-control group; (4) the relatively short duration (6 months) of the observation period."
    - **1.2** `[N]` [NOT VERIFIED IN TEXT]: "Patients weight and BMI were registered at four different time-points: baseline, i.e., when liraglutide was started (T0), and then after 1 (T1), 3 (T2), and 6 months (T3)."
    - **1.3** `[PY]` [NOT VERIFIED IN TEXT]: "The rate of persistence with liraglutide treatment was lower than the rate observed in liraglutide trials involving subjects that were not selected based on their psychiatric diagnosis (13, 14), this suggesting the possibility that patients with mood disorders may be less likely to adhere to liraglutide treatment, possibly because of their mental disorder."
    - **1.4** `[N]` [NOT VERIFIED IN TEXT]: "Descriptive statistics, Wilcoxon signed-rank test and Fisher exact test were performed."
    - **1.5** `[NA]`: "NO EVIDENCE IN TEXT"
    - **1.6** `[N]` [NOT VERIFIED IN TEXT]: "Descriptive statistics, Wilcoxon signed-rank test and Fisher exact test were performed."
    - **1.7** `[N]` [NOT VERIFIED IN TEXT]: "Descriptive statistics, Wilcoxon signed-rank test and Fisher exact test were performed."
    - **1.8** `[NA]`: "NO EVIDENCE IN TEXT"

**Candidate ratings:** Critical | Serious
**Your call:** ____________   **Note:** ____________

---

## 30728788 - D7 (Bias in selection of the reported result)

- **Reviewer 1 (claude:claude-opus-4-8)**: Moderate
- **Reviewer 2 (openai:gpt-5.6-sol)**: No information
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Every substantive quote from both reviewers (7.3 for A; 7.1, 7.2, and the implicit basis for 'Moderate' for B) is flagged as not found in the text, leaving only 'no evidence in text' entries that support No information but cannot be independently verified as complete; the discrepancy between a 'No information' and 'Moderate' rating is not resolvable from verified evidence alone.

**Reviewer 1 rationale.** The neuropsychiatric outcome is reported narratively with no pre-registered protocol or analysis plan, so selective reporting cannot be ruled out, though there is no positive evidence of result-driven selection. This yields moderate concern.

Reviewer 1 signalling answers:
    - **7.1** `[NI]` [NOT VERIFIED IN TEXT]: "no neuropsychiatric side-effects nor any liraglutide related worsening of the pre-existing mental condition were noted in our study"
    - **7.2** `[NI]` [NOT VERIFIED IN TEXT]: "All study data was collected retrospectively and no exam was specifically conducted for the purposes of this study."
    - **7.3** `[NI]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** The report provides no protocol, registration, or prespecified neuropsychiatric analysis plan. Consequently, selection from multiple outcome definitions or analyses cannot be assessed.

Reviewer 2 signalling answers:
    - **7.1** `[NI]`: "NO EVIDENCE IN TEXT"
    - **7.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **7.3** `[N]` [NOT VERIFIED IN TEXT]: "No patient showed a worsening of the psychiatric condition due to liraglutide treatment."

**Candidate ratings:** Moderate | No information
**Your call:** ____________   **Note:** ____________

---

## 41386528 - D4 (Bias due to deviations from intended interventions)

- **Reviewer 1 (claude:claude-opus-4-8)**: Moderate
- **Reviewer 2 (openai:gpt-5.6-sol)**: No information
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> All signalling questions are marked NI/NA with no verified supporting evidence except 4.6's quote, which merely confirms an EHR-based target trial emulation design and does not itself establish adherence/deviation information sufficient to support a 'Moderate' domain rating over 'No information'. Since the verified evidence does not clearly justify either reviewer's overall rating, this should be escalated to a human adjudicator.

**Reviewer 1 rationale.** The study estimates the effect of initiation (a target-trial ITT-analogue), which is appropriate, but it provides no information on switching, adherence, or co-interventions, leaving uncertainty about deviations.

Reviewer 1 signalling answers:
    - **4.1** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.2** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.3** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.4** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.5** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.6** `[NI]` [verbatim]: "We emulated a target trial using longitudinal electronic health records (EHRs) from Penn Medicine"

**Reviewer 2 rationale.** The study estimates an initiation effect, but it provides no information on adherence, discontinuation, switching, or follow-up co-interventions. Their potential impact on the neuropsychiatric result therefore cannot be assessed.

Reviewer 2 signalling answers:
    - **4.1** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.2** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.3** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.4** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.5** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.6** `[NA]`: "NO EVIDENCE IN TEXT"

**Candidate ratings:** Moderate | No information
**Your call:** ____________   **Note:** ____________

---

## 41386528 - D5 (Bias due to missing data)

- **Reviewer 1 (claude:claude-opus-4-8)**: Moderate
- **Reviewer 2 (openai:gpt-5.6-sol)**: Serious
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Reviewer A's 5.1 quote merely describes exposure/outcome ascertainment via diagnosis codes and doesn't clearly address missing data completeness, while Reviewer B's verified 5.1/5.2 quotes show data availability but neither reviewer has verified evidence on attrition/handling of missing data (5.3-5.5 largely NI in both). The verified quotes underdetermine whether missingness was substantial or well-handled, so the domain rating cannot be confidently resolved between Moderate and Serious.

**Reviewer 1 rationale.** Outcome data from EHR follow-up appear nearly complete, but the study is silent on handling of missing covariate data and on the comparability of missingness across groups, and coded diagnoses may undercount events.

Reviewer 1 signalling answers:
    - **5.1** `[PY]` [verbatim]: "The mean (SD) and median (IQR) follow-up duration for each outcome across treatment cohorts are presented in Table S7 ."
    - **5.2** `[N]` [verbatim]: "who newly initiated a GLP-1RA, SGLT2i, or DPP4i between January 1, 2019, and September 30, 2024"
    - **5.3** `[NI]` [verbatim]: "We estimated propensity scores (PS) using multivariate logistic regression including demographics, comorbidities, medications, laboratory, and healthcare utilization (see Table S5 )."
    - **5.4** `[NI]`: "NO EVIDENCE IN TEXT"
    - **5.5** `[NI]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** Diagnosis-code ascertainment can omit psychiatric events, and the study gives no completeness estimates by intervention group or missing-data analysis. This could materially bias a rare suicidality-related result, particularly toward the null.

Reviewer 2 signalling answers:
    - **5.1** `[N]` [verbatim]: "First, psychiatric conditions were identified using diagnosis codes, which may miss mild or subclinical disorders."
    - **5.2** `[NI]`: "NO EVIDENCE IN TEXT"
    - **5.3** `[NI]`: "NO EVIDENCE IN TEXT"
    - **5.4** `[NI]`: "NO EVIDENCE IN TEXT"
    - **5.5** `[N]` [verbatim]: "Future studies with longer follow-up, validated psychiatric assessments, and mechanistic exploration are needed to clarify this potential safety signal."

**Candidate ratings:** Moderate | Serious
**Your call:** ____________   **Note:** ____________

---

## 41491619 - D1 (Bias due to confounding)

- **Reviewer 1 (claude:claude-opus-4-8)**: Critical
- **Reviewer 2 (openai:gpt-5.6-sol)**: Serious
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Every quote from both reviewers is flagged [QUOTE NOT FOUND IN TEXT] and thus unverified, leaving no verified evidence to support either 'Critical' or 'Serious' for domain 1.1-1.8 signalling questions.

**Reviewer 1 rationale.** A single-arm design with no comparator and adjustment for only age and sex leaves confounding by indication (baseline psychiatric history, antidepressant use, diabetes/obesity severity) entirely uncontrolled, and the authors themselves acknowledge the design cannot exclude regression to the mean. For a neuropsychiatric effect estimate this is uncontrolled confounding at the most critical level.

Reviewer 1 signalling answers:
    - **1.1** `[Y]` [NOT VERIFIED IN TEXT]: "The study lacks a control group, which prevents us from excluding effects related to regression to the mean or the possibility of detec‑tion bias, which is inherent to our observational study design."
    - **1.2** `[N]` [NOT VERIFIED IN TEXT]: "We analysed changes in anthropometrics and mental health parameters from baseline to 4 months liraglutide 3.0 mg treatment using generalized least squares (GLS) models with measurement time point as predictor, adjusted for sex and age."
    - **1.3** `[NI]` [NOT VERIFIED IN TEXT]: "We excluded n = 8 patients who stopped treatment in the first 10 weeks of treatment (none of these patients reported stopping due to mental health com‑plaints)."
    - **1.4** `[N]` [NOT VERIFIED IN TEXT]: "All analyses were adjusted for age and sex."
    - **1.5** `[NA]`: "NO EVIDENCE IN TEXT"
    - **1.6** `[N]` [NOT VERIFIED IN TEXT]: "We analysed changes in anthropometrics and mental health parameters from baseline to 4 months liraglutide 3.0 mg treatment using generalized least squares (GLS) models with measurement time point as predictor, adjusted for sex and age."
    - **1.7** `[N]` [NOT VERIFIED IN TEXT]: "All analyses were adjusted for age and sex."
    - **1.8** `[NA]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** This uncontrolled one-arm study adjusted only for age and sex, leaving major baseline and time-related confounding unaddressed. Regression to the mean is especially material because improvements were concentrated among participants selected for poor baseline mental health.

Reviewer 2 signalling answers:
    - **1.1** `[Y]` [NOT VERIFIED IN TEXT]: "The study lacks a control group, which prevents us from excluding effects related to regression to the mean or the possibility of detection bias, which is inherent to our observational study design."
    - **1.2** `[N]` [NOT VERIFIED IN TEXT]: "In this observational, one-arm, real-world intervention study, we investigated changes in mental health parameters (depression and anxiety symptoms) as well as psychological wellbeing in 98 patients who received 4-month treatment with the GLP-1 analogue liraglutide 3.0 mg for obesity."
    - **1.3** `[NI]` [NOT VERIFIED IN TEXT]: "We excluded n = 8 patients who stopped treatment in the first 10 weeks of treatment (none of these patients reported stopping due to mental health complaints)."
    - **1.4** `[N]` [NOT VERIFIED IN TEXT]: "All analyses were adjusted for age and sex."
    - **1.5** `[NA]`: "NO EVIDENCE IN TEXT"
    - **1.6** `[N]` [NOT VERIFIED IN TEXT]: "We analysed changes in anthropometrics and mental health parameters from baseline to 4 months liraglutide 3.0 mg treatment using generalized least squares (GLS) models with measurement time point as predictor, adjusted for sex and age."
    - **1.7** `[NA]`: "NO EVIDENCE IN TEXT"
    - **1.8** `[NA]`: "NO EVIDENCE IN TEXT"

**Candidate ratings:** Critical | Serious
**Your call:** ____________   **Note:** ____________

---

## 41988822 - D6 (Bias in measurement of outcomes)

- **Reviewer 1 (claude:claude-opus-4-8)**: Low  ->(after reconciliation) Moderate
- **Reviewer 2 (openai:gpt-5.6-sol)**: Serious
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> judge output unparseable (JSONDecodeError('Expecting property name enclosed in double quotes: line 1 column 353 (char 352)'))

**Reviewer 1 rationale.** The within-person SCCS design ensures the outcome is measured identically across exposure and non-exposure periods, and depression is ascertained from routine coded diagnoses. Possible underdiagnosis is non-differential with respect to intervention, so any measurement error is unlikely to be materially biasing.

Reviewer 1 signalling answers:
    - **6.1** `[N]` [NOT VERIFIED IN TEXT]: "we included individuals with a first depression diagnosis"
    - **6.2** `[PN]` [NOT VERIFIED IN TEXT]: "we included individuals with a first depression diagnosis"
    - **6.3** `[PY]` [NOT VERIFIED IN TEXT]: "SCCS compares periods within the same individual"
    - **6.4** `[PN]` [verbatim]: "possible underdiagnosis of depression"
    - **6.4b** `[NA]`: "NO EVIDENCE IN TEXT"

**Reviewer 2 rationale.** Depression could be underdiagnosed, no validated outcome definition is presented in the supplied text, and assessors were not reported as blinded. Monitoring recommendations and healthcare contact around initiation create a plausible differential-detection mechanism.

Reviewer 2 signalling answers:
    - **6.1** `[PY]` [NOT VERIFIED IN TEXT]: "The US Food and Drug Administration (FDA) recommends monitoring for depression or suicidal thoughts and includes warnings concerning suicidal behaviour for some GLP1-RA formulations."
    - **6.2** `[PY]` [NOT VERIFIED IN TEXT]: "Using a self-controlled case series (SCCS) design, we assessed the risk of incident depression (Table S1) after GLP-1RA initiation."
    - **6.3** `[Y]` [NOT VERIFIED IN TEXT]: "SCCS compares periods within the same individual, eliminating time-invariant confounders such as genetics, socioeconomic status and baseline disease severity [6]."
    - **6.4** `[PY]` [verbatim, ellipsis-joined]: "A few limitations of this study include residual time-varying confounding (e.g., due to COVID-19 or co-medications, despite adjustment for age), limited sample size for some subgroups, heterogeneity due to differences in clinical practice and healthcare access across sites, possible underdiagnosis of depression and inability to consider recurrent depression events."

**Candidate ratings:** Low | Moderate | Serious
**Your call:** ____________   **Note:** ____________

---



# ==================== Stream-D ====================

# Escalation packet - human review queue

3 domain-cell(s) where the two reviewers disagreed, the reconciliation round failed to converge, and the blinded judge declined to resolve on the verified evidence. For each, the judge names the deciding signalling question and what evidence is missing; choose among the candidate ratings and fill in 'Your call'.

## 41883728 - D3 (Bias in classification of interventions)

- **Reviewer 1 (claude:claude-opus-4-8)**: Low
- **Reviewer 2 (openai:gpt-5.6-sol)**: Moderate
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Every quote from both reviewers is flagged [QUOTE NOT FOUND IN TEXT], leaving no verified evidence for any signalling question (3.1-3.3) to support either a Low or Moderate rating. Since all supporting evidence is unverified, the domain rating is genuinely underdetermined and must be escalated.

**Reviewer 1 rationale.** Intervention groups were clearly defined from prescription records fixed at least 90 days before the index date, precluding outcome-driven misclassification. Reliance on prescription (fill) records rather than dispensing/adherence is a minor limitation that does not materially threaten classification direction.

Reviewer 1 signalling answers:
    - **3.1** `[Y]` [NOT VERIFIED IN TEXT]: "The primary exposure was GLP-1 RA use, defined as any documented prescription fill for a GLP-1 RA (liraglutide, semaglutide, exenatide, and dulaglutide) at least 90 days prior to the index date"
    - **3.2** `[Y]` [NOT VERIFIED IN TEXT]: "The start date of prescription were identified using the Observational Medical Outcomes Partnership Common Data Model (CDM)."
    - **3.3** `[N]` [NOT VERIFIED IN TEXT]: "at least 90 days prior to the index date, based on prescription records in the electronic health record"

**Reviewer 2 rationale.** Groups were clearly classified using pre-index prescription records. Some exposure misclassification remains because prescription records may not represent actual use.

Reviewer 2 signalling answers:
    - **3.1** `[Y]` [NOT VERIFIED IN TEXT]: "Exposure was coded as a binary variable (1 = exposed, 0 = unexposed). Non-GLP-1RA users (unexposed) were individuals with no record of GLP-1RA prescriptions before the index date."
    - **3.2** `[Y]` [NOT VERIFIED IN TEXT]: "The start date of prescription were identified using the Observational Medical Outcomes Partnership Common Data Model (CDM)."
    - **3.3** `[N]` [NOT VERIFIED IN TEXT]: "The primary exposure was GLP-1 RA use, defined as any documented prescription fill for a GLP-1 RA (liraglutide, semaglutide, exenatide, and dulaglutide) at least 90 days prior to the index date, based on prescription records in the electronic health record."

**Candidate ratings:** Low | Moderate
**Your call:** ____________   **Note:** ____________

---

## 41883728 - D4 (Bias due to deviations from intended interventions)

- **Reviewer 1 (claude:claude-opus-4-8)**: Moderate  ->(after reconciliation) Serious
- **Reviewer 2 (openai:gpt-5.6-sol)**: Serious  ->(after reconciliation) Moderate
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Nearly all quotes from both reviewers are either unverified [QUOTE NOT FOUND IN TEXT] or marked 'NO EVIDENCE IN TEXT', leaving only one verified quote (4.3, Reviewer B, a data table fragment) that does not clearly support any specific domain rating. With almost no verified evidence for either signalling-question judgment, the correct rating is genuinely underdetermined and requires human review.

**Reviewer 1 rationale.** For a prescription-based 'starting the intervention' effect the binary exposure is broadly aligned with a target-trial intention-to-treat estimand, limiting deviation bias. However, unreported adherence and unaddressed SUD-specific co-interventions leave moderate uncertainty.

Reviewer 1 signalling answers:
    - **4.1** `[NI]` [NOT VERIFIED IN TEXT]: "Finally, medication exposure was inferred from prescription records and may not reflect actual adherence."
    - **4.2** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.3** `[NI]` [verbatim]: "Naltrexone 851 (7.5%) 851 (7.5%) 447 (6.8%) 389 (5.9%)"
    - **4.4** `[NI]` [NOT VERIFIED IN TEXT]: "medication exposure was inferred from prescription records and may not reflect actual adherence"
    - **4.5** `[NI]` [NOT VERIFIED IN TEXT]: "medication exposure was inferred from prescription records and may not reflect actual adherence"
    - **4.6** `[NI]` [NOT VERIFIED IN TEXT]: "Exposure was coded as a binary variable (1 = exposed, 0 = unexposed)"

**Reviewer 2 rationale.** Actual adherence and treatment implementation were not established, important psychiatric co-interventions were not shown to be balanced, and the analysis did not address these deviations. These limitations could materially affect an estimated effect of GLP-1 RA use.

Reviewer 2 signalling answers:
    - **4.1** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.2** `[NA]`: "NO EVIDENCE IN TEXT"
    - **4.3** `[PN]` [NOT VERIFIED IN TEXT]: "The following covariates: age, sex, race/ethnicity, type 2 diabetes or obesity status, and type of oral hypoglycemic agents were during matching."
    - **4.4** `[NI]`: "NO EVIDENCE IN TEXT"
    - **4.5** `[PN]` [NOT VERIFIED IN TEXT]: "Finally, medication exposure was inferred from prescription records and may not reflect actual adherence."
    - **4.6** `[N]` [NOT VERIFIED IN TEXT]: "The association between GLP-1 RA exposure and the odds of SUD was estimated to use conditional logistic regression, which accounted for the nested case control design."

**Candidate ratings:** Moderate | Serious
**Your call:** ____________   **Note:** ____________

---

## 41883728 - D5 (Bias due to missing data)

- **Reviewer 1 (claude:claude-opus-4-8)**: Low  ->(after reconciliation) Moderate
- **Reviewer 2 (openai:gpt-5.6-sol)**: No information
- **Reconciliation**: did not converge

**Why the judge escalated (deciding question + missing evidence):**
> Every quote from both reviewers is flagged as [QUOTE NOT FOUND IN TEXT], so no verified evidence supports either the 'No information' or 'Low' rating for any of the 5.1-5.5 signalling questions. With no verifiable textual support, the domain rating is underdetermined and requires human review of the source document.

**Reviewer 1 rationale.** Outcome data were complete by design and covariate missingness was low (<5%) and imputed via MICE rather than driving exclusions. Undercounting of coded psychiatric events is possible but is a measurement rather than a missing-data issue and is unlikely to be differential enough to change the judgement here.

Reviewer 1 signalling answers:
    - **5.1** `[PY]` [NOT VERIFIED IN TEXT]: "In addition, participants with missing outcome variables, under 18 years old, and those with no history of diabetes or/and obesity were excluded."
    - **5.2** `[N]` [NOT VERIFIED IN TEXT]: "Non-GLP-1RA users (unexposed) were individuals with no record of GLP-1RA prescriptions before the index date."
    - **5.3** `[PN]` [NOT VERIFIED IN TEXT]: "Missing data for covariates (<5% for most variables) were handled using multiple imputations by chained equations."
    - **5.4** `[NI]` [NOT VERIFIED IN TEXT]: "Missing data for covariates (<5% for most variables) were handled using multiple imputations by chained equations."
    - **5.5** `[PY]` [NOT VERIFIED IN TEXT]: "Missing data for covariates (<5% for most variables) were handled using multiple imputations by chained equations."

**Reviewer 2 rationale.** The extent and distribution of exclusions for missing outcomes are not reported. Covariate missingness was low and multiply imputed, but that does not resolve uncertainty about missing outcomes.

Reviewer 2 signalling answers:
    - **5.1** `[NI]` [NOT VERIFIED IN TEXT]: "In addition, participants with missing outcome variables, under 18 years old, and those with no history of diabetes or/and obesity were excluded."
    - **5.2** `[N]` [NOT VERIFIED IN TEXT]: "Non-GLP-1RA users (unexposed) were individuals with no record of GLP-1RA prescriptions before the index date."
    - **5.3** `[N]` [NOT VERIFIED IN TEXT]: "Missing data for covariates (<5% for most variables) were handled using multiple imputations by chained equations."
    - **5.4** `[NA]`: "NO EVIDENCE IN TEXT"
    - **5.5** `[NA]`: "NO EVIDENCE IN TEXT"

**Candidate ratings:** Low | Moderate | No information
**Your call:** ____________   **Note:** ____________

---

